Skip to Primary Navigation

Regulatory uncertainty brings risk and opportunity to pharma in 2025, says Jeff Lemay

Montage with Jeff Lemay and a wall of prescription drugs.
GRIP Montage: Spencer Platt/Getty Images/Private

CCO Jeff Lemay reflects on his time at Jazz Pharmaceuticals and asseses the road ahead for compliance and legal teams in the pharma sector.

New market and policy initiatives in 2025 create a truly challenging healthcare environment, but they also present businesses and stakeholders with the opportunity to expand into some new areas, such as new technology leveraging artificial intelligence (AI).

Functions are rarely siloed any longer, as teams must collaborate to navigate ever-changing supply

Subscribe for free to continue reading

Read more articles like this one with our free plan, or get our Premium plan for access to all content – including our 5,000+ article archive, exclusive interviews, podcasts, and more.

Already have an account? Sign in